Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Common drug propellants undergo insignificant metabolism by body, says Metrics scientist at AAPSIn a poster presentation at AAPS, Dr. Brad Gold at Metrics Contract Services demonstrates that two propellants commonly used in prescription inhalers are exhaled primarily unchanged
By: Metrics Inc. Dr. Thomas B. “Brad” Gold, vice president of pharmaceutical development, shared his findings at the American Association of Pharmaceutical Scientists annual meeting in his poster presentation, “Determination of Trifluoroacetic Acid in Human Urine Using 19F Nuclear Magnetic Resonance after Inhalation of 1,1,1,2-Tetrafluoroethane or Dichlorodifluoromethane." Gold’s study examined asthmatic patients dosed with metered-dose inhalers containing either 1,1,1,2-tetrafluoroethane or dichloromethane to determine whether the propellants’ “What we demonstrated was that these compounds were not being metabolized by the body – and that’s a good thing, because it shows that these are safe inhalants to use in metered drug products,” Gold explained. “As an industry, we want to ensure that propellants are safe to use by patients.” Both 1,1,1,2-tetrafluoroethane and dichlorodifluoromethane are gases the pharmaceutical industry uses in the manufacturing of metered dose inhalants, such as bronchodilators for patients with asthma. Gold said he anticipates that the pharmaceutical industry will discover within the next 10 years even better ways of delivering inhaled drug products for the benefit of patients. About Metrics Contract Services Metrics Contract Services is a full-service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms. Our areas of expertise include quality formulation development; Located in Greenville, N.C., Metrics Contract Services is a proud member of the Mayne Pharma family. Learn more online. About Mayne Pharma Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange . The company develops and manufactures branded and generic product globally – either directly or through distribution partners – while applying its drug-delivery expertise for contract development and manufacturing services. Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world. Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|